🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas

Recruitingn/aAges any - 24 YearsAllAzienda Ospedaliera Ospedale Infantile Regina Mar…
NCT04621201 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a heterogeneous group of tumors arising in connective tissues embryologically derived from the mesenchyme. For some of these tumors relapse and mortality rates are still significantly high. Therefore, further studies are needed to better understand pathogenetic processes underlying sarcomas to offer new and more effective treatments. Next generation sequencing (NGS) has opened new frontiers for cancer research allowing to identify somatic or constitutional mutations known or yet unknown with the aim to better understand carcinogenesis. The establishment of the genomic profile of the tumor could also help clinicians to personalize patients treatment based on their genetic and molecular alterations.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients with histologically confirmed Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma at first diagnosis. 2. Patients with confirmed relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma 3. Written informed consent signed by the patient, or parents or legal representative to perform molecular analysis of the tumor sample. 4. Patients aged ≤24 years 5. Pathological review of tumor samples. 6. Availability of fresh tumor sample from newly diagnosed or relapsed/refractory cancer and 10 ml of EDTA peripheral blood sample. Centralization of paraffin-embedded tumor sample might be optional. Exclusion Criteria: * 1\. Known history of active HIV, HCV, or HBV infection 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient undergoing surgery biopsy or the quality of the data.
💊

What it tests

  • observation and biopsy
📍

Where

10 sites
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
Torino, Italy
Istituto Ortopedico Rizzoli
Bologna, Italy
Policlinico S.Orsola-Malpighi
Bologna, Italy
Azienda ospedaliero-universitaria Meyer
Florence, Italy
Istituto Giannina Gaslini
Genova, Italy
Istituto Nazionale Tumori
Milan, Italy
Presidio Ospedaliero Gaetano Pini | ASST Pini-CTO
Milan, Italy
Fondazione I.R.C.C.S. Policlinico San Matteo
Pavia, Italy

…and 2 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy